alzheimer disease
Alzheimer's disease research is at a pivotal moment following recent FDA approvals of amyloid-targeting antibodies (lecanemab, donanemab), which have validated the amyloid hypothesis after decades of failures and opened the door to disease-modifying treatment in early symptomatic disease. Trials now focus on earlier intervention, combination approaches, and non-amyloid targets including tau, neuroinflammation, and synaptic loss.
Current trials investigate anti-tau antibodies, microglial activators, BACE inhibitors, GLP-1 agonists repurposed for neuroprotection, and lifestyle interventions for prevention in APOE4 carriers. Plasma biomarkers (p-tau217, AΞ²42/40 ratio) are increasingly used for enrollment screening, replacing expensive PET scans.
Most disease-modifying trials require early-stage disease (mild cognitive impairment or mild dementia) with confirmed amyloid pathology by PET or CSF biomarkers.
Disease Burden & Epidemiology
Alzheimer's disease is the most common cause of dementia, accounting for 60–80% of dementia cases globally. Approximately 55 million people worldwide live with dementia, a number projected to reach 139 million by 2050 as the global population ages. In the United States, the Alzheimer's Association estimates 6.9 million Americans aged 65 and older currently live with Alzheimer's dementia, with a new diagnosis occurring every 65 seconds. Women are disproportionately affected: roughly two-thirds of Americans with Alzheimer's are women, reflecting both longer lifespan and possible biological sex differences in disease progression. The annual economic cost in the US exceeds $360 billion in direct medical and long-term care costs, not accounting for the estimated 18 billion hours of unpaid caregiving provided by family members. Risk is substantially elevated by the APOE ε4 allele — present in approximately 25% of the general population — which increases lifetime risk two- to threefold for heterozygotes and eight- to twelvefold for homozygotes. Age remains the strongest risk factor: prevalence doubles approximately every five years after age 65, reaching 32% among those aged 85 and older.
Key Research Trends & Landmark Studies
The CLARITY AD trial established lecanemab (Leqembi) as the first anti-amyloid antibody to achieve both significant amyloid clearance and a statistically meaningful slowing of clinical decline β€” 27% reduction in clinical worsening on the CDR-Sum of Boxes scale at 18 months β€” leading to FDA accelerated approval in January 2023 and full approval in July 2023. The TRAILBLAZER-ALZ 2 trial subsequently demonstrated donanemab's benefit, with 35% slowing of decline in patients with low-to-medium tau burden, particularly striking in the early-stage subgroup. These approvals have transformed trial design: most current disease-modifying trials now require amyloid confirmation (via PET or CSF) and target MCI or very mild dementia stages. The A4 Study (Anti-Amyloid Treatment in Asymptomatic Alzheimer's) tested solanezumab in cognitively normal but amyloid-positive individuals β€” a prevention model now being extended with newer agents. The AHEAD 3-45 trial is actively enrolling cognitively normal adults at risk to evaluate lecanemab in the preclinical stage, representing the leading edge of Alzheimer's prevention research.
Patient Guide: How to Find & Join a Trial
Patients or family members seeking Alzheimer's clinical trial participation should act early β€” most disease-modifying trials require mild cognitive impairment (MCI) or mild dementia stage, and the window for enrollment closes as the disease progresses. The first step is obtaining a formal cognitive assessment (neuropsychological testing) and ideally an amyloid status determination via PET scan or lumbar puncture for CSF biomarkers, as these are required for most current disease-modifying trials. Memory clinics at major academic medical centers offer the most comprehensive diagnostic workup and trial access. The Alzheimer's Association Trial Match (trialmatch.alz.org) and the ClinicalTrials.gov condition filter are the most reliable resources for locating enrolling studies by location. Caregivers should be involved in the enrollment process from the start, as many trials require a study partner who can confirm day-to-day functional status and accompany the participant to visits.